76P: Long-term survival outcomes with first-line (1L) osimertinib monotherapy and subsequent treatment (tx) patterns: Final analysis of a real-world (rw) study in US patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC)
Griesinger F, Wang X, Karia P, Cooper M, Servidio L, Jedy-Agba E, Nieva J, Doroshow D. 76P: Long-term survival outcomes with first-line (1L) osimertinib monotherapy and subsequent treatment (tx) patterns: Final analysis of a real-world (rw) study in US patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC). Journal Of Thoracic Oncology 2025, 20: s56-s57. DOI: 10.1016/s1556-0864(25)00271-0.Peer-Reviewed Original ResearchEpidermal growth factor receptor-mutatedLong-term survival outcomesOsimertinib monotherapyFirst-lineSurvival outcomesUS patientsMonotherapyOsimertinibNSCLCPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply